CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by about 4% and said it would have to take a new $5 billion impairment charge.
May 11, 2026 06:30 AM EDTUpdated 03:35 PM
CSL sinks to nine-year low on revenue warning, $5B write-down
CSL’s stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by about 4% and said it would …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
There is no hiding from the bloody mess at CSL, one of Australia’s global success stories. Can it recover?
Shares of biotech company CSL plunged after the company announced that Chief Executive Officer Paul McKenzie will step down.
Commonwealth Bank, CSL, Cochlear – ASX heavyweights and once investor favourites – are getting their reckonings.
Australia’s CSL pledges to ‘deeply examine’ what has gone wrong at former stock market darling
C3 AI shares tumbled after it announced preliminary financial results and a restructuring of its global sales and services…
Big banks leading the Australian sharemarket may be coming to an end, global asset managers warn, on the back of $30bn being…
‘Collision with reality’: The $100 billion downfall of an Aussie giant
The day CBA shares crashed back down to earth
‘Regime shift’: ASX warning after CBA bloodbath
Power is shifting in CSL’s horrible, no good, very bad week
SGX asks Mary Chia if it can continue operating amid court battle with creditor
